Clinical trials have shown that anticoagulation with vitamin K antagonists (VKAs), e.g. warfarin, decreases the risk of stroke in patients with atrial fibrillation (AF); however, increased bleeding risk is one of the safety concerns. The primary objective was to conduct a systematic review of the published literature, assessing the risk of major bleeding and mortality in patients with AF treated with VKAs.
Introduction
Atrial fibrillation (AF), the most common cardiac arrhythmia encountered in clinical practice, represents a growing clinical and economic burden. 1 Atrial fibrillation is considered an epidemic, affecting 1 to 1.5% of the population in the developed world, and is projected to grow at least three-fold by 2050. 2 The prevalence of AF is markedly increasing in our ageing society. The Rotterdam study, a large, European, population-based study, reported an overall prevalence of 5.5%, with age-specific prevalence ranging from 0.7% of people aged 50-59 years to 17.8% of those aged 85 years and older. 3 Strongly associated with increased risk of mortality and morbidity due to stroke and other vascular complications, AF is a major public health burden. 4 Although many clinical trials have shown that anticoagulation with warfarin and other vitamin K antagonists (VKAs) decreases the risk of ischaemic stroke in patients with AF, concerns remain regarding their long-term safety, mainly increased risk of bleeding, and prescribing practices for VKAs. Warfarin therapy is complicated because of the wide inter-individual variation in response and dose requirements for adequate anticoagulation, narrow therapeutic range [international normalized ratio (INR), 2.0 -3.0 for AF], need for chronic anticoagulation monitoring, potentially life-threatening interaction with numerous foods and drugs, and long onset and offset of action. These factors all contribute to the significant underuse of warfarin in patients with AF at risk for stroke despite clear indication for its use. 5, 6 Vitamin K antagonists are also one of the drug classes creating the highest rates of emergency admissions to the hospital in the elderly. 7 A number of published studies have reported risk of bleeding and mortality associated with warfarin and other VKAs; however, no systematic review has been performed to date to collate the available evidence. Thus, this study systematically assembled the best evidence from randomized clinical trials (RCTs) and observational studies conducted in the real-life setting to evaluate the risk of bleeding and mortality in the population with AF treated with warfarin and other VKAs.
Methods

Literature search and data extraction
This review was performed systematically in an unbiased manner by using a pre-specified protocol and an explicit, reproducible plan for literature search and synthesis. Study designs such as RCTs, prospective cohort studies, and retrospective study designs were included in this review. Searches to identify RCTs were of literature published from 1960 to 7 March 2012; searches to identify observational studies were of literature published from January 1990 to 7 March 2012, as observational clinical data published before 1990 are unlikely to be relevant to current treatment practices and resource patterns. No limitations on publication language or geographical perspective were applied. Translation of the articles to English was done as required.
The following electronic databases were searched: MEDLINE, EMBASE, BIOSIS, and the Cochrane Library. In addition, conference abstracts from 2010 to March 2012 from the American Heart Association, International Society on Thrombosis and Haemostasis, and European Society of Cardiology were searched. Search terms included combinations of free text and medical subject headings. Separate sets of terms were used for the health condition of interest (AF), the treatment of interest (VKAs), and the study types of interest (RCTs and observational studies). The specific search strategies for MEDLINE are shown in Appendix 1. Study inclusion was performed at two levels in parallel by two researchers. At level 1, titles and abstracts of all identified articles were screened. Articles were excluded if their abstracts fit any of the pre-specified exclusion criteria: case reports, letters, comments, editorials, and reviews. The full text of all papers determined to be eligible at level 1 was reviewed at level 2 to ensure that they met the inclusion criteria. All disagreements at various stages were resolved by consensus with input from an experienced senior researcher.
For each eligible study that passed both levels of screening, data were extracted by one researcher and verified with the original sources by a second researcher. To focus the review on large, comprehensive studies, only studies that included 300 or more patients receiving VKA treatment were selected. This sample size cut-off point was chosen so that, in the absence of an event, the upper limit of the 95% confidence interval (CI) for the event would be 1%, according to Hanley's rule. 8 
Data synthesis
Results of this systematic literature search were mainly summarized qualitatively using descriptive statistics. Qualitative synthesis consisted of detailed evidence tables and figures that included information on the study design, population size and characteristics (INR target range, percentage of time in INR range, CHADS2 criteria, and prescribing information), and results (i.e. mortality and bleeding in AF). Some data imputations were necessary to derive number of events, total patient-years, and rates per 100 patient-years. If not directly reported, patient-years for the group were calculated from the sum of the length of follow-up for each participant. When only two of these three estimates (number of events, total patient-years, and rate) were reported, the third was imputed using simple calculations. Univariate summaries, including the median, interquartile range (IQR), and weighted mean (weighted by sample size), were produced and are presented in a box-and-whisker plot.
This review assessed a potentially optimized VKA usage within the last two decades that might have impacted the incidence of bleeding and mortality. To assess this, we used a weighted linear regression model. For RCTs, the publication year was used, while for observational studies the midpoint of the observed period was taken, as these studies included data over a longer time period. Where observational studies did not give the start and end dates of the observation period, we imputed these dates from the year of publication and the average follow-up for patients.
Results
Study identification and characteristics
A total of 3286 records were retrieved after the searches were performed, and 47 studies with a sample size of at least 300 patients were included in the review. Of the included studies, 16 were RCTs and 31 were observational studies with either a prospective or retrospective study design. The search results are summarized in Figure 1 , PRISMA flowchart. Detailed summaries of the included studies are provided in Appendices 2 and 3.
Randomized controlled trials
All included RCTs were active-controlled trials that were published from 1989 through 2011 and designed to compare newer drugs with VKAs. Their primary objective was to evaluate frequency of fatal and non-fatal stroke (ischaemic or haemorrhagic), intracranial haemorrhage, or other clinically significant arterial embolism in patients who were treated with dose-adjusted VKA. The sample size in the warfarin treatment arm ranged from 319 to 9081 and the cumulative patient-years were 61 563. In all studies, the mean age of patients was greater than 60 years (range, 63 -82 years) and most had a majority of male patients (range, 49 to 70%). Study length ranged from 5 months to 3 years. Among patients in the VKA group, the proportion of time in which the intensity of anticoagulation was in the therapeutic range calculated from all INR values during the study ranged from 42 to 86%. 9, 10 In most RCTs, the target therapeutic INR range of 2.0 -3.0 was used, with the exception of four studies. In one study, warfarin dosage was adjusted to achieve an INR range of 1.7 -3.0; 11 whereas in three other studies, warfarin dosage was adjusted to achieve an INR range of 2-4.5. 
Observational studies
All 31 observational studies were published during the years 2001 to 2011. Data sources for these studies included registries, claims databases, hospital and anticoagulation clinic electronic records (inpatient and outpatient), and national mortality statistics databases. The year midpoint during which the data were collected for these studies was from 1997 to 2009. Most of the published studies were from data sources in the USA; other countries included the UK, Italy, Sweden, Denmark, Norway, Japan, Hong Kong (China), Australia, and Israel. The sample size in these studies ranged from 328 to 70 057 and the cumulative patientyears was 484 241. The included studies had a mean age range of 64 -83 years and a greater proportion of male patients (.50%).
Bleeding
All randomized trials provided a definition for major bleeding, which was consistent across most trials ( Table 1) . The most frequent definition for major bleeding was bleeding that was fatal or overt bleeding with a drop in haemoglobin level of at least 20 g/L or requiring transfusion of at least 2 units packed blood cells, or haemorrhage into a critical anatomical site (e.g. intracranial, retroperitoneal). The overall median incidence of major bleeding in the included RCTs was 2.1 per 100 patient-years (range, 0.9 -3.4 per 100 patient-years; IQR, 1.5 -3.1 per 100 patient-years) (Figure 2) , and the weighted mean was 2.8 per 100 patient-years.
In observational studies, the definition of major bleeding varied across studies ( Table 2) . Some studies focused mainly on gastrointestinal bleeding, 30, 35, 46, 51, 52 whereas other studies included patients that had bleeding from other anatomical sites. The incidence of major bleeding in the observational studies was similar to that in the RCTs-median 2.0 per 100 patient-years (range, 0.2 -7.6 per 100 patient-years; IQR, 1.5 -3.8 per 100 patientyears); weighted mean, 4.4 per 100 patient-years-but variation was greater in the observational studies ( Figure 2 ). Regression models (weighted) were used to examine the relationship between potentially optimized VKA usage over time and major bleeding, and results showed that bleeding rates or bleeding Non-cerebral and non-fatal bleeding events were classified as major if they were severe, i.e. they made it necessary to hospitalize the patient, administer a blood transfusion, or perform surgery reporting tended to increase over the last decade in both RCTs and observational studies; the increase was statistically significant in observational studies ( Figure 3 ). The regression model estimates the increase in major bleeding rate over a period of 10 years to be 3.84 per 100 patient-years (95% CI, 0.68 to 7.00, P ¼ 0.019), for observational studies and 1.00 per 100 patient-years (95% CI, 20.05 to 2.05, P ¼ 0.061) for RCTs. Although some observations on the scatter plots lie outside the CIs, these may have minimal impact on the fitted regression if the sample sizes are relatively small, as these are weighted regressions.
Mortality
In most clinical studies, mortality was evaluated as a secondary endpoint and was commonly defined as death due to vascular diseases or all-cause mortality. Of the 16 RCTs, 15 reported all-cause mortality and 11 reported vascular mortality, of which 10 reported both all-cause and vascular mortality; data are presented in Table 3 .
To assess and compare all-cause and vascular mortality, summary data are presented for the 10 trials that report both. Median allcause mortality in patients treated with VKAs was 4.5 per 100 patient-years (range, 2.9-8.0 per 100 patient-years; IQR, 3.8-5.8 per 100 patient-years) ( Figure 4 ) and the weighted mean was 4.3 per 100 patient-years. Incidence of vascular mortality was 2.6 per 100 patient-years (range, 1.5-6.7 per 100 patient-years; IQR, 2.1 to 3.2 per 100 patient-years) ( Figure 4 ) and the weighted mean was 2.3 per 100 patient-years. As a proportion of all-cause mortality, 52% (weighted mean) of deaths were classified as vascular (minimum, 31%; median, 62%; and maximum, 91%; Table 3 ). Although not investigated statistically, it is possible that the proportion and Hu et al.
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AF, atrial fibrillation; Hb, haemoglobin; ISTH, International Society on Thrombosis and Haemostasis; RBC, red blood cells; RCTs, randomized controlled trials.
Bleeding in atrial fibrillation patients receiving Vitamin K antagonists Major bleeds included GI haemorrhages that resulted in an inpatient admission. Only the first episode of a major bleed per cohort member during the study period was included. Number of major bleeds and patient-years were imputed from the N and %, which in turn enabled rate per 100 patient-years to be imputed of all deaths classified as vascular has reduced over time ( Figure 5) . In observational studies, all-cause mortality was reported in only 11 of 31 studies. Owing to heterogeneity in the methodology and the large differences in the reliability and validity of death reporting in the data sources (and hence in the reported mortality rates) and the relatively low proportion of included observational studies reporting mortality, we could not further summarize these data in a meaningful way. Within the RCT data, by using the publication year as a proxy to changing VKA management patterns over time, we found no clear evidence of a relationship with all-cause mortality, but some evidence of decreasing vascular mortality over time ( Figure 5) . Regression models (weighted) were used, and the models estimated a non-significant decrease in all-cause mortality rate over a period of 10 years to be 20.78 (95% CI, 22.66 to 1.09, P ¼ 0.362) and a significant decrease in the vascular mortality rate over a period of 10 years to be 21.60 (95% CI, 22.77 to 20.44, P ¼ 0.013).
Discussion
This systematic review of patients with AF confirms the assertion that there is a risk of major bleeding when treated with VKAs; this was confirmed by the overall incidence rates reported in RCTs and in observational studies conducted in the real-life clinical setting. The overall median rate of major bleeding was similar in the RCTs and the observational studies, but there was greater variation in the results reported in the observational studies. A sensitivity analysis performed in RCTs also including studies with smaller sample sizes (,300) gave very similar results. The IQRs of major bleeding rates were similar in RCTs (1.5 -3.1) and observational studies (1.5 -3.8), suggesting that the observed increased variability in observational studies are in the extremes. The largest observed major bleeding rate in observational studies occurred in the largest study. 40 Including this study from the US-Medicare claims database considerably increased the weighted mean bleeding rate from 3.1 to 4.4. We critically examined some of the potential reasons for heterogeneity in the bleeding and mortality rates observed in the publications using the study year as a proxy to changing management patterns in clinical practice. Over the years, there has been greater awareness of the warfarin benefit-to-risk ratio, and there are efforts to stay within a narrow therapeutic range (INR, 2.0-3.0 for AF) by stringently monitoring anticoagulation parameters, and scrutinizing administration of co-medications and dietary products. Regression models (weighted) examined this relationship and results showed that bleeding rates tended to increase over time in both RCTs and observational studies; the increase was statistically significant in observational studies. A number of factors could all potentially contribute to this increase over time: changing definition of major bleeding over time; heightened awareness of major bleeding and therefore increased reporting; and changes in patterns of prescribing VKAs due to greater awareness of the positive benefit-to-risk ratio, leading to the more likely treatment of vulnerable patients that are at high risk of stroke, but also at risk of bleeding.
Other potential factors may include concurrent use of drugs that interact with VKAs, thereby increasing the risk of serious bleeding, which is a widespread problem in clinical practice. Many drugs interact with the metabolism of VKAs, and the number increases as new drugs enter the market. These drugs can lead to over-anticoagulation, under-anticoagulation, or increased bleeding risk by pathways independent of INR, such as altered platelet function. Enhanced sensitivity to oral anticoagulation with VKAs, resulting in a higher risk for bleeding that varies across patient populations, may be attributed to co-morbid conditions such as chronic renal failure, 57 hepatic dysfunction, and old age. Not all studies have shown consistent results, making it difficult to get a clear view of the association of VKA use in real-life clinical settings with major bleeding and mortality. The evidence gathered in this review suggests that there is a paucity of high-quality and consistently reported data for major bleeding. One of the limitations of this review is heterogeneity across the included observational studies in terms of patient population, study objectives, year of publication (which, for example, influences how VKA treatment is monitored), definitions of outcomes, and length of follow-up. In addition, quality of design and execution of observational studies can differ dramatically. These sources of heterogeneity are evident in the differences in the minimum and maximum major bleeding rates observed in the RCTs and observational studies. There was also lack of mortality data in observational studies. For studies that used claims database records, there is uncertainty about the accuracy and completeness of medical record documentation. Also, information of variables known to be associated with the risk of bleeding (such as specific co-morbidities 58 or concomitant use of antiplatelets) was not reported sufficiently to incorporate them into our analyses. Published after the cut-off date for the searches conducted for this study, a large (over 48 000 patients receiving VKAs only), wellconducted, high-quality observational study reported a major bleeding rate of 1.9 per 100 patient-years in patients treated with VKAs only over an observation period of 2005-2008. 59 This finding is consistent with the median major bleeding rate observed across our included studies (2.0 per 100 patient-years). Another large observational study, published after the cut-off date, was in an AF cohort of 125 195 Canadian patients starting Bleeding in atrial fibrillation patients receiving Vitamin K antagonists warfarin therapy. 60 In this study the bleeding rate per 100 patientyears was 3.8, with major bleeding defined as a visit to an emergency department or an admission to hospital for haemorrhage during warfarin therapy. Bleeding rates were highest in the first 30 days of warfarin therapy (11.8 per 100 patient-years) compared with the remainder of the 5-year follow-up period (3.4 per 100 patient-years). It could have been hypothesized that the bleeding rates in observational studies would be higher than those in RCTs, given that patients in RCTs are typically a more selective group than those receiving anticoagulation in routine care. In addition, it is widely known that VKA control in RCTs is systematically better than in routine care, probably relating to study investigators being more skilful in the handling of warfarin. 61 That this did not lead to markedly different bleeding rates may be attributed to the fact that adverse event reporting in RCTs is typically more systematic and complete than in observational studies. Also, bleeding events can be prospectively defined and recorded in RCTs (often even with adjudication by an independent review board). Such consistent criteria are more difficult to apply in retrospective database studies. The limitations of oral anticoagulation by VKAs, particularly safety concerns, have prompted the development and availability of new oral anticoagulants, such as the oral direct thrombin inhibitors (e.g. dabigatran etexilate) and oral factor Xa inhibitors (e.g. rivaroxaban and apixaban). These new drugs may cause less bleeding and do not require stringent monitoring like VKAs, and therefore may be useful alternatives to VKAs.
